BACKGROUND Risk mitigation for most teratogenic medications relies on risk
communication via drug label, and prenatal exposures remain common. Information on the …

Data on the real long-term influences of in utero drug exposure in pregnant women on
childhood development are scarce and remain not well determined and depend on the …

Inflammatory Bowel Disease (IBD) presents distinct challenges during pregnancy due to its
influence on maternal health and pregnancy outcomes. This literature review aims to dissect …

The fields of gastroenterology and hepatology, along with endoscopic practice, have seen
significant changes and innovations to practice in just the past few years. These practice …

Background Inflammatory bowel disease (IBD) affects young adults of reproductive age, and
questions related to pregnancy and breastfeeding are common in clinical practice. Most …

The peak incidence of inflammatory bowel disease (IBD) coincides with a woman's prime
reproductive years. The management of IBD during pregnancy can be challenging for …

Introduction: Women with inflammatory bowel disease (IBD) endorse a tremendous amount
of concern about medication exposure during pregnancy and their effects on the fetus …

Background In women with inflammatory bowel disease, at least 3 months of preconception
corticosteroid-free remission (CFREM) is recommended by experts in current consensus …

Introduction Ustekinumab is a human IgG1 kappa monoclonal antibody that targets the p40
subunit of interleukin (IL)-12 and IL-23 and blocks the binding of these cytokines to the IL …

Autoimmune and inflammatory disorders, including inflammatory bowel disease (IBD),
commonly affect women of childbearing age, warranting the use of immunomodulatory …